Dr. Angelo de Claro of the FDA's Oncology Center of Excellence, in a news release, said, "This marks the first FDA approval ...
MedPage Today on MSN
Breast cancer drug wins approval despite rejection by agency advisors
Oral SERD camizestrant lands indication for use in novel first-line treatment strategy ...
Hot on the heels of the approval for AstraZeneca’s breast cancer drug Etcamah, Guardant Health has been given the green light ...
Accelerated approval targets acquired endocrine resistance, specifically ESR1-mutant disease emerging on aromatase inhibitor ...
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...
The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...
Dear Dr. Roach: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.
The U.S. Food and Drug Administration has expanded treatment options for adult patients with advanced breast cancer, ...
Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...
DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results